Tideglusib
Tideglusib is a potent and irreversible small molecule glycogen synthase kinase 3 inhibitor.
Clinical trials
Tideglusib has been evaluated in clinical trials for:- Alzheimer's disease and progressive supranuclear palsy. Both clinical trials were discontinued in 2011 and 2012 due to lack of efficacy
- Congenital/juvenile-onset myotonic muscular dystrophy type I.
Research
Tideglusib is or has been under investigation for multiple applications:- Tooth repair mechanisms that promotes dentine reinforcement of a sponge structure until the sponge biodegrades, leaving a solid dentine structure. In 2016, the results of animal studies were reported in which 0.14 mm holes in mouse teeth were permanently filled.
- Preclinical in vitro studies were carried out for neuroblastoma and ovarian cancer with significant ROS-induced apoptosis.
- Arrhythmogenic right ventricular cardiomyopathy as of 2025.